Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 29, 2015 12:00 ET | Source: VALNEVA

VALNEVA: Communiqué de mise à disposition du rapport financier annuel 2014

Communiqué de mise à disposition du rapport financier annuel 2014 Lyon (France), le 29 avril 2015 - Valneva SE ("Valneva"), société de biotechnologie parmi les leaders de l'industrie du vaccin...
April 29, 2015 12:00 ET | Source: VALNEVA

VALNEVA published its Annual Financial Report 2014

Valneva published its Annual Financial Report 2014 Lyon (France), April 29, 2015 - Valneva SE ("Valneva"), a leading pure play vaccines biotech company, announced today that it has published its...
April 02, 2015 12:00 ET | Source: VALNEVA

VALNEVA : Déclaration d'actions et de droits de vote - Mars 2015

Dénomination sociale : VALNEVA Adresse du siège social : 70, rue Saint Jean de Dieu, 69007 LYON Marché réglementé Euronext Paris de Nyse Euronext - Compartiment B Date de la déclaration : 2 avril...
March 26, 2015 02:56 ET | Source: VALNEVA

VALNEVA Announces Approval of an EB66(R)-based Prototype Influenza Vaccine in Japan

LYON, France, March 26, 2015 (GLOBE NEWSWIRE) -- The vaccine was developed by the Chemo-Sero Therapeutic Research Institute (Kaketsuken) in collaboration with GlaxoSmithKline using Valneva's...
March 26, 2015 02:30 ET | Source: VALNEVA

VALNEVA Announces Approval of an EB66®-based Prototype Influenza Vaccine in Japan

Valneva Announces Approval of an EB66®-based Prototype Influenza Vaccine in Japan The vaccine was developed by the Chemo-Sero Therapeutic Research Institute (Kaketsuken) in collaboration with...
March 26, 2015 02:30 ET | Source: VALNEVA

VALNEVA annonce l'approbation au Japon d'un vaccin prototype contre la grippe, produit sur la lignée cellulaire EB66®

Valneva annonce l'approbation au Japon d'un vaccin prototype contre la grippe, produit sur la lignée cellulaire EB66® Vaccin développé par Chemo-Sero Therapeutic Research Institute (Kaketsuken)...
March 20, 2015 12:46 ET | Source: VALNEVA

VALNEVA confirme son éligibilité au PEA-PME

Valneva confirme son éligibilité au PEA-PME Lyon (France), le 20 mars, 2015 - Valneva SE ("Valneva"), société de biotechnologie parmi les leaders de l'industrie du vaccin humain et vétérinaire,...
March 20, 2015 02:30 ET | Source: VALNEVA

VALNEVA Reports Annual Results 2014 :the company announces a significant improvement to its EBITDA and a strong reduction of its net loss

Valneva Reports Annual Results 2014 The company announces a significant improvement to its EBITDA and a strong reduction of its net loss compared to prior-year pro forma result Significant...
March 20, 2015 02:30 ET | Source: VALNEVA

VALNEVA présente ses résultats 2014 : le Groupe annonce l'amélioration significative de son EBITDA et une forte réduction de sa perte nette

Valneva présente ses résultats annuels 2014 Le Groupe annonce l'amélioration significative de son EBITDA et une forte réduction de sa perte nette, à données comparables Progrès significatifs vers...
March 20, 2015 02:30 ET | Source: VALNEVA

VALNEVA Reports Annual Results 2014: the company announces a significant improvement to its EBITDA and a strong reduction of its net loss

Valneva Reports Annual Results 2014 The company announces a significant improvement to its EBITDA and a strong reduction of its net loss compared to prior-year pro forma result Significant...